Nia Novianti Siregar

Nia Novianti Siregar

Auto-generated profile, based on publicly available information

Nia Novianti Siregar

Division of Hematology and Medical Oncology, Department of Internal Medicine, Dharmais Cancer Hospital, Jakarta, Indonesia

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 September 2018 in Journal of the ASEAN Federation of Endocrine Societies
Verified
Journal Article
Open access
NSNia Novanti Siregar
Nia Novanti Siregar
PSPradana Soewondo
Pradana Soewondo
ISImam Subekti
Imam Subekti
MMMuhadi Muhadi
Muhadi Muhadi
Seventy-Two Hour Mortality Prediction Model in Patients with Diabetic Ketoacidosis: A Retrospective Cohort Study

10 March 2026 in Blood Global Hematology
Verified
Journal Article
Open access
JCJason Yongsheng Chan
Jason Yongsheng Chan
NSNia Novianti Siregar
Nia Novianti Siregar
ALAnna Mira Lubis
Anna Mira Lubis
NYNoorainun Yusof
Noorainun Yusof
SOShin Yeu Ong
Shin Yeu Ong
GGGin Gin Gan
Gin Gin Gan

23 August 2024 in South Asian Journal of Cancer
Verified
Journal Article
Open access
PDF file
AKAndree Kurniawan
Andree Kurniawan
RCRahmat Cahyanur
Rahmat Cahyanur
AGAngela Giselvania
Angela Giselvania
ATAngeline Tancherla
Angeline Tancherla
FWFelix Wijovi
Felix Wijovi
AAArdi Ardian
Ardi Ardian
Introduction International recommendation supports induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CCRT) as a new standard of care for locally advanced nasopharyngeal cancer (LA-NPC) which give a survival benefit. TPF is one of the IC regimens which consists of docetaxel (75 mg/m2, 1 hour infusion), cisplatin (75 mg/m2, 0.5–3 hours), and 5-fluorouracil (600 mg/m2, 4 days). Previous retrospective study in Chinese population reported low-dose TPF (L-TPF), consists of docetaxel (60 mg/m2), cisplatin (65 mg/m2), and then 5-fluorouracil (550 mg/m2/d; 5 days), showed better tolerance and compliance rates, with similar efficacy to high-dose TPF (H-TPF). Thus, we aim to evaluate the current evidence of the effect of L-TPF compared with H-TPF on survival and tolerance as IC in LA-NPC. Methods Data were collected from PubMed, PubMed Central, and Science Direct, using combinations of keywords related to neoadjuvant chemotherapy (NAC) or IC, TPF dose regimen, and LA-NPC. The included studies investigated the efficacy and toxicity of IC with a TPF regimen. The quality of each included study was assessed using the Newcastle–Ottawa scale for cohort studies and the JADAD scale for randomized controlled trial (RCT). Only moderate- and good-quality studies were further evaluated in the meta-analysis. Results A total of six studies consisting of 509 NAC patients were included. All the studies evaluated overall survival (OS) and progression-free survival (PFS). Quantitative analysis showed that L-TPF + CCRT significantly showed good OS (hazard ratio [HR] = 0.50; 95% confidence interval [CI], 0.33–0.76; p = 0.001) but not PFS (HR = 0.45; 95% CI, 0.16–1.25; p = 0.13). Common chemotoxicities that were found in both groups were neutropenia and anemia. Conclusion L-TPF IC had a significant positive effect on the survival of LA-NPC patients. Further, larger multicenter RCT studies are needed to focus on evaluating the optimal TPF regimen dose in LA-NPC. Received: 29 March 2024 Accepted: 26 July 2024 Article published online: 23 August 2024 © 2024. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/) Thieme Medical and Scientific Publishers Pvt. Ltd. A-12, 2nd Floor, Sector 2, Noida-201301 UP, India